ACLX - Arcellx stock jumps 12% after week of declines

Arcellx (ACLX) shares jumped 12% on Monday following a week of declines. Shares of the biotech group opened at $11.23 and hit a high of $11.97 in early afternoon. The stock recently changed hands at $11.94, up 12%, at approximately 1:15 p.m. Based in Maryland, Arcellx has been developing cell-based immunotherapies for the treatment of blood cancers. Its lead product candidate, CART-ddBCMA, is in Phase 1 testing for the treatment of multiple myeloma. Arcellx went public in early February, offering 8.25M shares priced at $15 per share to raise gross proceeds of around $123.8M.

For further details see:

Arcellx stock jumps 12% after week of declines